NCT02386800 2026-03-16CINC424A2X01B Rollover ProtocolNovartisPhase 4 Active not recruiting279 enrolled
NCT03975829 2026-02-13Pediatric Long-Term Follow-up and Rollover StudyNovartisPhase 4 Active not recruiting163 enrolled
NCT01735955 2024-02-08Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored StudyNovartisPhase 4 Completed57 enrolled 8 charts
NCT01957176 2022-12-30A Rollover Study to Provide Continued Treatment With EltrombopagNovartisPhase 4 Completed22 enrolled 9 charts
NCT02228382 2021-12-30Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase InhibitorsPfizerPhase 4 Terminated163 enrolled 27 charts
NCT01201811 2019-12-05Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)CelgenePhase 4 Completed44 enrolled 26 charts
NCT00171899 2017-02-23Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)NovartisPhase 4 Completed80 enrolled
NCT01368523 2016-11-16Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 TrialNovartisPhase 4 Completed19 enrolled
NCT02317159 2014-12-15Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid LeukemiaCttqPhase 4 Unknown90 enrolled
NCT00081926 2009-11-23Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaNovartisPhase 4 Completed112 enrolled